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Abstract
Introduction: The present study was designed to determine the effects of continuously infused norepinephrine
(NE) plus (1) terlipressin (TP) or (2) arginine vasopressin (AVP) or (3) placebo on sublingual microcirculation in septic
shock patients. The primary study end point was a difference of ≥ 20% in the microvascular flow index of small
vessels among groups.
Methods: The design of the study was a prospective, randomized, double-blind clinical trial. NE was titrated to
maintain mean arterial pressure (MAP) between 65 and 75 mmHg after establishment of normovolemia in 60
septic shock patients. Thereafter patients (n = 20 per group) were randomized to receive continuous infusions of
either TP (1 μg/kg/hour), AVP (0.04 U/minute) or placebo (isotonic saline). In all groups, open-label NE was adjusted
to maintain MAP within threshold values if needed. The sublingual microcirculatory blood flow of small vessels was
assessed by sidestream dark-field imaging. All measurements, including data from right heart catheterization and
norepinephrine requirements, were obtained at baseline and 6 hours after randomization.
Results: TP and AVP decreased NE requirements at the end of the 6-hour study period. The data are medians
(25th and 75th interquartile ranges (IQRs)): 0.57 μg/kg/minute (0.29 to 1.04) vs. 0.16 μg/kg/minute (0.03 to 0.37) for
TP and 0.40 μg/kg/minute (0.20 to 1.05) vs. 0.23 μg/kg/minute (0.03 to 0.77) for AVP, with statistical significance of
P < 0.05 vs. baseline and vs. placebo. There were no differences in sublingual microcirculatory variables, systemic
hemodynamics, oxygen transport and acid-base homeostasis among the three study groups during the entire
observation period. The proportions of perfused vessels increased in relation to baseline within all study groups,
and there were no significant differences between groups. The specific data were as follows (median (IQR)): 9.7%
(2.6 to 19.8) for TP, 8.9% (0.0 to 17.8) for AVP, and 6.9% (3.5 to 10.1) for placebo (P < 0.05 vs. baseline for each
comparison), as well as perfused vessel density 18.6% (8.6 to 36.9) for TP, 20.2% (-3.0 to 37.2) for AVP, and 11.4%
(-3.0 to 19.4) for placebo (P < 0.05 vs. baseline for each comparison).
Conclusions: The present study suggests that to achieve a MAP of 65 to 75 mmHg in septic patients treated with
NE, the addition of continuously infused low-dose TP or AVP does not affect sublingual microcirculatory blood flow.
In addition, our results suggest that microcirculatory flow abnormalities are mainly related to other factors (for
example, volume status, timing, hemodynamics and progression of the disease) rather than to the vasopressor per se.
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The current guidelines on the management of patients
with septic shock recommend the use of vasopressor
agents, such as norepinephrine (NE) or dopamine, to
increase peripheral vascular resistance and preserve organ
perfusion following adequate volume therapy [1]. Since
microvascular dysfunction plays a crucial role in the
pathophysiology of septic shock and organ dysfunction
[2,3], special attention should be paid to the effects of
vasopressor agents on tissue perfusion and microcircula-
tory blood flow [4,5]. In this regard, recent studies have
demonstrated that the administration of NE to achieve a
target MAP between 60 and 90 mmHg does not worsen
microcirculatory perfusion [6,7]. Whether the vasopressor
per se, rather than other factors (for example, volume
status, timing, hemodynamics and progression of the dis-
ease), plays a role in preserving or deteriorating capillary
perfusion in septic shock is still not fully understood.
Despite their efficacy in reducing catecholamine require-
ments and stabilizing hemodynamics in patients with
vasodilatory shock, there are concerns that the addition of
vasopressinergic agents may further impair microcircula-
tion because of their pronounced vasoconstrictive potency.
Although V1 receptor agonism may cause excessive vaso-
constriction, concomitant stimulation of vasodilatory V2
receptors may potentially improve microcirculatory blood
flow. Whether the reduction of catecholamine require-
ments following hemodynamic support with vasopressors
has a positive effect on the microcirculation is likewise
unknown. Despite these relevant open questions, the avail-
able data on the effects of vasopressinergic agonists on the
microcirculation in human septic shock are scarce and
remain to be determined.
The objective of the present randomized, controlled,
double-blind clinical study was therefore to compare, for a
predefined goal MAP in patients with septic shock treated
with NE, the effects of adding continuously infused low-
dose terlipressin (TP), arginine vasopressin (AVP) or
placebo on microcirculatory perfusion as judged by modi-
fications of sublingual microvascular blood flow using
sidestream dark-field (SDF) imaging [8].
Materials and methods
Patients
After approval by the local Institutional Ethics Committee,
the present study was performed in an 18-bed multidisci-
plinary ICU at the Department of Anesthesiology and
I n t e n s i v eC a r eo ft h eU n i v e r s i t yo fR o m e“La Sapienza.”
Informed consent was obtained from the patients’ next of
kin. Enrollment of patients started in November 2008 and
ended in March 2010. We enrolled patients who fulfilled
the criteria of septic shock [1] and required NE to main-
tain MAP ≥ 65 mmHg despite appropriate volume
resuscitation (pulmonary arterial occlusion pressure
(PAOP) = 12 to 18 mmHg and right atrial pressure
(RAP) = 8 to 12 mmHg) [1].
Exclusion criteria were: age < 18 years, pronounced
cardiac dysfunction (that is, cardiac index (CI) ≤ 2.2 L/
minute/m
2 in the presence of PAOP > 18 mmHg), severe
liver dysfunction, significant valvular heart disease, present
coronary artery disease, pregnancy, present or suspected
acute mesenteric ischemia or vasospastic diathesis (for
example, Raynaud’s syndrome or related diseases).
All patients underwent lung-protective mechanical ven-
tilation using a volume-controlled mode, which was
adjusted to maintain plateau < 30 cmH2O[ 1 ] .I na l l
patients, positive end-expiratory pressure was set at a level
ranging from 7 to 15 cmH2O. The ventilatory settings
remained unchanged throughout the study period. All
patients were appropriately analgo-sedated using sufenta-
nil and midazolam and received intravenous hydrocorti-
sone (300 mg/day) as a continuous infusion. Activated
protein C was administered at the discretion of the attend-
ing physician.
Measurements
Systemic hemodynamic monitoring of the patients
included the use of a pulmonary artery catheter (7.5-
French; Edwards Lifesciences, Irvine, CA, USA) and a
radial artery catheter. MAP, RAP, mean pulmonary arterial
pressure (MPAP) and PAOP were measured at end-
expiration. Heart rate was analyzed by continuous record-
ing of an electrocardiogram with ST segments monitored.
CI was measured using the continuous thermodilution
technique (Vigilance II; Edwards Lifesciences). Arterial
and mixed venous blood samples were taken to measure
oxygen tension and saturation as well as carbon dioxide
tension, standard bicarbonate and base excess (BE). Mixed
venous oxygen saturation (SvO2) was measured discon-
tinuously by intermittent mixed venous blood gas analyses.
Microvascular network
Microvascular blood flow was visualized by means of a
SDF imaging device (MicroScan; MicroVision Medical,
Amsterdam, The Netherlands) equipped with a 5× mag-
nification lens [8]. The optical probe was applied to the
sublingual mucosa after gentle removal of saliva with a
gauze swab. Three discrete fields were captured with cau-
tion to minimize motion artefacts. Individual sequences
of approximately 15 seconds were analyzed offline with
the aid of dedicated software (Automated Vascular Ana-
lysis 3.0 software; Academic Medical Center, University
of Amsterdam, Amsterdam, The Netherlands) in a ran-
domized fashion by a single investigator who was una-
ware of the study protocol. The “De Backer Score” was
calculated as described previously [8]. It is based on the
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Page 2 of 10principle that the density of the vessels is proportional to
the number of vessels crossing arbitrary lines. In this
score, three equidistant horizontal and three equidistant
vertical lines are drawn on the screen. The De Backer
Score can be calculated as the number of the small, med-
ium and large vessels crossing the lines divided by the
total length of the lines [8]. Vessel density was calculated
as the total vessel lengths divided by the total area of the
image [8]. Both indices were automatically calculated by
the utilized software. Perfusion was then categorized by
eye as present (normal continuous flow for ≥ 15 seconds),
sluggish (decreased but continuous flow for ≥ 15 sec-
onds), absent (no flow for ≥ 50% of time) or intermittent
(no flow for < 50% of time) [8]. The proportion of per-
fused vessels (PPVs) was calculated as follows:
100×(total number of vessels - [no ﬂow+intermittent ﬂow])/total number of vessels
Perfused vessel density (PVD) was calculated by multi-
plying vessel density by the PPVs [8]. Vessel size was
determined with the aid of a micrometer scale. Small ves-
sels were defined as vessels with a diameter < 20 μm.
Since our investigation was primarily focused on small
vessels, calculations were separately performed for vessels
with a diameter smaller than 20 μm. Microvascular flow
index of small vessels (MFIs) was used to quantify micro-
vascular blood flow in these vessels. Therefore, flow was
characterized as absent 0, intermittent 1, sluggish 2, or
normal 3 [8]. For each patient, values obtained from the
three mucosa fields were averaged. To assess flow hetero-
geneity between the different areas investigated, we used
the heterogeneity index. The latter was calculated as the
highest site flow velocity minus the lowest site flow velo-
city, divided by the mean flow velocity of all sublingual
sites [8]. Percentage changes from baseline for all vari-
ables were calculated as follows [9]:
dVariable = 100 × [(Value6 hours/ValueBL) − 1]
Study design
After having established normovolemia (PAOP = 12 to 18
mmHg and CVP = 8 to 12 mmHg) [1] and a MAP ≥ 65
mmHg using NE, patients were randomized to one of
three study groups. Whereas patients allocated to the TP
group received a continuous TP infusion of 1 μg/kg/hour,
patients in the AVP group were treated with a continuous
infusion of AVP of 0.04 U/minute. The control group
received a continuous infusion of isotonic saline as pla-
cebo. All the investigated drugs were administered in a
blinded fashion. In all three groups, open-label NE was
titrated to maintain goal MAP between 65 and 75 mmHg
if necessary. Fluid challenge (6% hydroxyethylstarch 130/
0.4) was performed to maintain PAOP and CVP at base-
line ± 3 mmHg during the 6-hour study period.
Systemic hemodynamic variables, microcirculatory
flow variables, blood gases and NE requirements were
determined at baseline and 6 hours after randomization.
After the 6-hour intervention period, study drugs were
discontinued, and in all three groups open-label NE was
titrated to maintain MAP between 65 and 75 mmHg.
Statistical analyses
The primary end point of the present study was the dif-
ference in MFIs between groups after 6 hours of treat-
ment. An ap r i o r ianalysis of sample size revealed that
20 patients per group were required to demonstrate a
minimum difference in means of 20% between groups
for the primary end point with an assumed standard
deviation of 20%, a test power of 80% and an a error of
5%. The above-mentioned assumptions were based on
prior experience with the respective methodology [10].
Data are expressed as medians (25th and 75th percen-
tiles) if not otherwise specified. SigmaStat 3.10 software
(Systat Software, Inc., Chicago, IL, USA) was used for
statistical analysis. Baseline and demographic data were
compared with an analysis of variance (ANOVA) on
ranks or a c
2 test as appropriate. Differences in micro-
vascular and hemodynamic variables between groups
were analyzed by ANOVA on ranks. Time-dependent
changes within each group were determined with a
signed-rank test. P < 0.05 was considered statistically
significant for all tests.
Results
Demographic data
Baseline characteristics of the study patients, including
age, gender, Simplified Acute Physiology Score II, origin
of septic shock and time from onset of septic shock until
study drug infusion were similar among groups (Table 1).
In addition, there were no significant differences between
groups at baseline in any of the investigated hemody-
namic, metabolic or microcirculatory variables, except
for lower PVD in the AVP group than in the control
group (Figure 1). Activated C protein was administered
in eight patients in the NE group and in six patients in
both TP and AVP groups.
Hemodynamic and oxygen transport variables and
norepinephrine requirements
Systemic and pulmonary hemodynamics as well as acid-
base variables and fluid input are given in Table 2. There
were no significant differences among groups, except for a
lower hemoglobin concentration in the TP group than in
the control group at 6 hours. NE requirements were mark-
edly reduced after 6 hours in the TP group (0.57 μg/kg/
minute (0.29 and 1.04) vs. 0.16 μg/kg/minute (0.03 to
0.37); with each P < 0.001 vs. controls and baseline values)
and in the AVP group (0.40 μg/kg/minute (0.20 and 1.05)
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vs. controls and baseline values) as compared to both
baseline and the control group (0.66 μg/kg/minute (0.51
to 0.92) vs. 0.73 μg/kg/minute (0.63 to 0.83); P =0 . 1 1v s .
baseline) (Figure 2).
Microcirculatory variables
Absolute and relative changes (compared to baseline) of
microcirculatory variables of the three study groups are
presented in Figures 1 and 3. PVD, PPV and MFIs sig-
nificantly increased in all groups (each P < 0.05 vs. base-
line). The heterogeneity index tended to decrease in all
groups, but this change was significant only in the con-
trol group. None of the absolute or relative changes in
microcirculatory variables was significantly different
among the three study groups.
Discussion
The major finding of the present study is that in fluid-
resuscitated septic shock patients treated with NE to
maintain a MAP between 65 and 75 mmHg, the addi-
tion of continuously infused low-dose TP and AVP does
not affect sublingual microcirculatory blood flow com-
pared with placebo. Although TP and AVP were effec-
tive in reducing NE requirements, there were no
clinically relevant effects on the microcirculation.
The current guidelines for the treatment of septic shock
recommend the use of vasopressor agents to achieve a
MAP ≥ 65 mmHg [1]. While pressure-guided resuscitation
is usually effective in restoring MAP, microcirculatory
blood flow may not be linearly improved [4,5,11]. This
assumption is supported by studies demonstrating that
although the administration of NE to achieve incremental
targets for MAP between 60 and 90 mmHg does not
negatively affect the microcirculation, it does not correct
preexisting microcirculatory flow abnormalities [6,7]. Con-
versely, in the presence of normovolemia, an improvement
of microcirculatory perfusion can theoretically be obtained
by vasodilator agents, because it dilates afferent arterioles
while reducing efferent venous pressure [11,12]. From a
physiological perspective, AVP and (to a lesser extent) TP
may exert beneficial effects on the microcirculation com-
pared to NE, because they also exert some vasodilatory
effects by nitric oxide (NO) release secondary to V2 recep-
tor stimulation [13-15].
Despite the different actions of these agents on V1a and
V2 receptors, the present study failed to demonstrate dif-
ferences between the combinational therapies with TP
plus NE, AVP plus NE and sole NE infusion in terms of
microcirculatory variables. This finding may imply either
that TP and AVP have similar intrinsic activity on V1a
and V2 receptors or that V2-mediated vasorelaxant effects
[13-15] are attenuated and not hemodynamically rele-
vant. The latter assumption is supported by the fact that
the study drugs were administered in the setting of pro-
gressed septic shock, where V2-mediated vasodilation
may be impaired as a result of overproduction of NO. On
the other hand, the tendency toward lower NE require-
ments in the TP group may be explained by different
intrinsic activities of the respective AVP and TP concen-
trations at the V1a receptor site.
Recently, the safety of supplemental AVP has been
demonstrated in the Vasopressin and Septic Shock Trial
(VASST), with a potential survival benefit in patients
with less severe septic shock that may support adminis-
tration of the drug in the early phase of the disease [16].
Moreover, experimental studies [17,18] and clinical stu-
dies [19] have provided evidence of a superiority of first-
line TP over AVP or sole NE in stabilizing cardiovascular
hemodynamics in septic shock. In addition, it has been
reported that selective V2 receptor antagonism rather
than V2 receptor stimulation stabilized cardiopulmonary
hemodynamics while attenuating metabolic acidosis and
tissue injury, thereby limiting organ dysfunction in early
Table 1 Characteristics of the study patients
Characteristics Terlipressin (n = 20) Arginine vasopressin (n = 20) Control (n = 20) P value
Age, years 65 (51 to 71) 71 (48 to 78) 66 (58 to 75) P = 0.31
Male gender (%) 55% 70% 60% P = 0.61
SAPS II 50 (46 to 59) 53 (49 to 58) 54 (46 to 59) P = 0.83
Cause of septic shock (n) P = 0.50
Cholangitis 1
Meningitis 1 3
Necrotizing fasciitis 1 2 2
Peritonitis 6 5 5
Pancreatitis 1
Pneumonia 12 8 13
Onset of septic shock, hours* 37 (21 to 44) 35 (27 to 45) 34 (22 to 52) P = 0.89
SAPS II, Simplified Acute Physiology Score II. Data are medians (25th and 75th percentiles) unless otherwise indicated. *Onset of septic shock defines the time
elapsed from the onset of septic shock until administration of study drug.
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Figure 1 Absolute changes in microcirculatory variables. AVP, arginine vasopressin; BL, baseline; DBS, De Backer Score; HI, heterogenity
index; MFI, microvascular flow index of small vessels (Ø < 20 μm); NE, norepinephrine; CTRL, control; PPV, proportion of perfused vessels; PVD,
perfused vessel density; TP, terlipressin; VD, vessel density. Solid lines, median; dashed lines, mean; boxes, 25th and 75th percentiles; whisker caps,
10th and 90th percentiles.
aP < 0.05,
aaP < 0.01,
aaaP < 0.001 vs. BL;
bP < 0.05 vs. CTRL.
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Page 5 of 10Table 2 Hemodynamic and metabolic data of the study patients
Parameters TP (n = 20) AVP (n = 20) Control (n = 20) P value
CI (L/min/m
2)
Baseline 3.8 (3.1 to 5.4) 4.0 (3.2 to 4.9) 4.0 (3.5 to 4.6) 0.96
6 hours 4.0 (3.1 to 5.1) 3.5 (3.0 to 4.0)* 4.0 (3.4 to 4.9) 0.28
HR (bpm)
Baseline 104 (86 to 113) 99 (83 to 119) 104 (86 to 111) 1.00
6 hours 88 (82 to 100) 91 (75 to 117) 91 (85 to 114) 0.64
MAP (mmHg)
Baseline 71 (68 to 75) 72 (69 to 75) 71 (68 to 75) 0.97
6 hours 74 (72 to 75) 72 (68 to 75) 74 (68 to 75) 0.31
MPAP (mmHg)
Baseline 30 (27 to 35) 31 (28 to 36) 29 (27 to 32) 0.42
6 hours 29 (24 to 33) 29 (26 to 34) 31 (26 to 33) 0.65
PAOP (mmHg)
Baseline 16 (14 to 19) 18 (16 to 20) 18 (15 to 20) 0.26
6 hours 17 (13 to 20) 18 (15 to 22) 18 (14 to 20) 0.45
RAP (mmHg)
Baseline 13 (10 to 15) 15 (12 to 17) 13 (10 to 14) 0.13
6 hours 13 (10 to 15) 14 (11 to 16) 11 (10 to 14) 0.22
LVSWI (g/m/m
-2)
Baseline 29 (24 to 41) 26 (24 to 35) 30 (22 to 37) 0.85
6 hours 32 (26 to 44) 24 (23 to 39) 30 (21 to 44) 0.11
DO2I (mL·min
-1/m
2)
Baseline 437 (391 to 604) 460 (396 to 677) 470 (399 to 550) 0.92
6 hours 461 (364 to 587) 416 (369 to 473) 509 (431 to 600) 0.13
O2-ER (%)
Baseline 25 (23 to 30) 26 (22 to 30) 31 (27 to 36) 0.05
6 hours 32 (25 to 35) 29 (24 to 38) 35 (29 to 41) 0.15
SvO2 (%)
Baseline 75 (68 to 77) 73 (67 to 80) 69 (66 to 76) 0.30
6 hours 70 (66 to 77) 70 (59 to 77) 67 (59 to 72) 0.26
Hba (g/dL)
Baseline 8.3 (8.0 to 9.5) 8.9 (8.3 to 9.8) 8.7 (8.0 to 9.3) 0.50
6 hours 8.3 (8.0 to 8.8)* 8.6 (8.1 to 9.7) 9.0 (8.6 to 10.0) 0.005
pHa (-log10c(H
+))
Baseline 7.30 (7.24 to 7.34) 7.31 (7.27 to 7.37) 7.31 (7.28 to 7.36) 0.62
6 hours 7.39 (7.31 to 7.43) 7.33 (7.28 to 7.40) 7.31 (7.25 to 7.37) 0.08
BE (mmol/L)
Baseline -3.9 (-7.0 to -1.2) -3.1 (-8.0 to 1.8) -2.9 (-5.9 to 1.6) 0.65
6 hours -2.2 (-4.7 to 2.4) -3.4 (-5.7 to 1.5) -4.0 (-6.2 to 0.5) 0.41
Lactate (mmol/L)
Baseline 1.8 (1.2 to 2.9) 2.3 (1.4 to 3.6) 2.5 (1.9 to 3.0) 0.67
6 hours 2.1 (1.5 to 2.8) 2.3 (1.4 to 3.6) 2.6 (2.1 to 3.7) 0.45
Fluid input (mL/6 hours)
Baseline n/a n/a n/a n/a
6 hours 875 (790 to 950) 910 (830 to 975) 895 (800 to 990) 0.51
AVP, arginine vasopressin; BE, base excess; CI, cardiac index; DO2I, systemic oxygen delivery index; Hba, arterial hemoglobin concentration; HR, heart rate; LVSWI,
left ventricular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; O2-ER, oxygen extraction ratio; PAOP, pulmonary arterial
occlusion pressure; pHa, arterial Potentia hydrogenii; RAP, right atrial pressure; SvO2, mixed venous oxygen saturation; TP, terlipressin; VO2I, systemic oxygen
consumption index. Data are medians (25th and 75th percentiles). *P < 0.05 vs. control.
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the present study and the available literature appears to
show that there are not only advantages of selective [21]
or relatively selective V1a receptor agonists, such as TP
over mixed vasopressinergic agonists like AVP, but also,
more importantly, that the relationship between vaso-
pressinergic receptor agonists and the timing of adminis-
tration (early vs. late) may be crucial in preserving or
deteriorating organ function.
In line with the above-referenced studies [16-21], and
supported by the results of our present study, it appears
that delayed administration of TP or AVP may not
translate into microcirculatory advantages over sole NE,
although TP and AVP are still effective in reducing cate-
cholamine requirements. The right timing of administer-
ing vasopressinergic agents, however, is still debated. In
this context, Kampmeier et al. [22] recently reported
that early TP infusion reduced catecholamine and fluid
requirements compared with delayed TP therapy and
placebo in ovine septic shock.
In harmony with the effects on the microcirculation,
and in line with previous experimental and clinical stu-
dies [17-19,23], we did not notice differences in arterial
pH or in lactate concentrations following TP or AVP
administration, suggesting a lack of drug-related impair-
ment of cellular oxygenation as well as the absence of dif-
ferences in resuscitation quality between groups. In this
context, it is also important to note that the multicenter
VASST study [16] demonstrated no differences between
AVP and sole NE in the rate of overall adverse events.
Interestingly, we observed a time-dependent improve-
ment in some microcirculatory variables in all study
groups. The beneficial evolu t i o ni nt h eN Eg r o u po v e r
time is in agreement with a recent study by Boerma et al.
[24], who reported an increase in MFIs even in the placebo
group. In this regard, it may be possible that some patients
experienced a beneficial evolution with respect to their
course of disease during the study period. Another possi-
ble explanation is that fluid therapy administered over a
short observational period, such as in our protocol,
resulted in further recruitment of the microcirculation in
some of the patients [25,26]. However, it is important to
note that only limited amounts of fluids were given (see
Table 2) and that changes were similar between groups.
In the present study, we did not find differences between
the study drugs when vasopressor support was titrated to
maintain MAP between 65 and 75 mmHg. Nonetheless,
we cannot exclude the possibility that a lower threshold
MAP would have generated different results, thereby
further reducing excessive NE requirements. It also cannot
be excluded that the involvement of inflammatory
mechanisms mediated by leukocyte activation and cyto-
kine release, as well as hemorheological factors related to
the progression of the disease, affected the microcircula-
tory blood flow more than the choice of vasopressor. Eva-
luation of these factors, however, was beyond the scope of
the present study.
Our study has some limitations that we must acknowl-
edge. First, our protocol did not allow us to draw conclu-
sions regarding whether the observed findings were
related mainly to a direct effect of vasopressinergic agents
on microcirculation or to a concomitant reduction of NE
dosage per se. However, we chose this protocol to mimic
the clinical scenario, in which AVP and TP are currently
used as adjuvant vasopressor support in established, NE-
dependent septic shock. Since there are no equivalent
doses of AVP and TP for continuous infusion, we decided
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Figure 3 Relative changes in microcirculatory variables. Data represent relative changes from baseline (BL) at 6 hours. AVP, arginine
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Page 8 of 10to evaluate the effects of fixed doses of the study drugs on
microcirculatory blood flow while maintaining the thresh-
old MAP with titrated NE infusion. In this regard, it might
be argued that a weight-adjusted TP dose was compared
with a fixed AVP dose, and thus the chosen doses might
not have been pharmacologically equivalent. Therefore, it
is possible that the TP dose was relatively higher than the
AVP dose. Second, we chose changes in MFIs as the pri-
mary end point of this study. Since we investigated only a
small number of septic shock patients treated over a brief
period, the risk of false-negative or false-positive results in
a study with numerous microcirculatory variables has to
be taken into account. Moreover, the marginally signifi-
cant difference in PVD at baseline (P = 0.04) represents a
limitation of the present study. However, the fact that > 20
variables were compared with a significance threshold of
5% indicates a high probability of significant differences in
the absence of true clinical relevance. Since the difference
in PVD was the only one observed at baseline, it probably
had no major impact on the quality of the present data.
However, it cannot be definitively excluded that the oppo-
site is the case. In addition, we cannot rule out the possibi-
lity of divergent microcirculatory effects in response to
more prolonged administration of the study drugs. When
looking at the technique adopted in the present study, we
have to acknowledge that whereas SDF imaging allows
real-time imaging of the intact microcirculation in the
clinical setting, the assessment of some microcirculatory
variables that result from this technique remain semiquan-
titative and the data reliability may be affected by level of
technical expertise and interobserver bias. Furthermore,
we investigated the changes in microvascular perfusion of
the sublingual mucosa, which may not necessarily be
representative of alterations in other tissues [2,27,28].
Whether applying a different method to determine fluid
responsiveness would have generated different results can-
not be answered by the present study.
Conclusions
In summary, this study is the first to show that in patients
with fluid-resuscitated septic shock treated with NE to
maintain MAP between 65 and 75 mmHg, the addition of
TP, AVP or placebo has similar effects on the sublingual
microcirculation. At the investigated doses, the addition of
TP and AVP reduced NE requirements without changing
sublingual microvascular blood flow. The results of the
present study suggest that microcirculatory flow abnorm-
alities are mainly related to other factors (for example,
volume status, timing, hemodynamics and progression of
the disease) rather than to the vasopressor per se.
Key messages
￿ In septic patients treated with NE to achieve a MAP
of 65 to 75 mmHg, the addition of continuously
infused TP or AVP does not affect sublingual micro-
circulatory blood flow.
￿ The potential advantages of TP or AVP over sole
NE with regard to microcirculation might be limited
to the early phases of septic shock.
￿ Microcirculatory flow abnormalities are related
mainly to other factors (for example, volume status,
timing, hemodynamics and progression of disease)
rather than to the vasopressors per se.
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